Metformin and Galantamine Combination Modestly Improves Sarcopenia Symptoms

Therapies that reuse existing drugs with sizable bodies of human data tend to move more rapidly to the clinic than is the case for better, more ambitious approaches that break new ground. Greater speed in reaching the clinic means a lower cost of development, and this economic incentive is why so much of clinical development consists of drug reuse and only modestly effective therapies. In the case of sarcopenia, the age-related loss of muscle mass and strength, sizable funding is presently devoted to the development of small molecule therapies that do not produce greater gains than resistance exercise. A good deal of what we might think of as muscle aging is in fact disuse. More generally, and not just in the matter of sarcopenia, it would be good to see greater ambition, more development of first in class therapies in the research and development community - but people follow incentives, particularly when a great deal of funding is involved. Rejuvenate Biomed, a pioneering clinical-stage platform and pipeline company committed to enhancing lifelong health through innovative therapeutics, today announces breakthrough functional outcome results from its Phase 1b trial of lead candidate RJx-01 for the treatment of sarcopenia. RJx-01 is a proprietary combination of metformin and galantamine that was identified by the company's in-house drug discovery platform and has shown to have beneficial effects on various preclinical models of sarcopenia. The recent exploratory cli...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs